title: Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine.
abstract: Health technology assessment (HTA) is a crucial science that influences the responsible and evidence-based transition of new discoveries from laboratory to applications in the clinic and society. HTA has recently moved "upstream" so as to assess technologies from their onset at their discovery, design, or planning phase. Biomarker research is relatively recent in oral health, but growing rapidly with investments made to advance dentistry and oral health and importantly, to build effective bridges between oral health and systems medicine since what happens in oral health affects systems pathophysiology, and vice versa. This article offers a synthesis of the latest trends and approaches in early phase HTA, with a view to near future applications in oral health, systems medicine, and biomarker-guided precision medicine. In brief, this review underscores that demonstrating health outcomes of biomarkers and next-generation diagnostics is particularly challenging because they do not always influence long-term outcomes directly, but rather impact subsequent care processes. Biomarker testing costs are typically less of a barrier to uptake in practice than the biomarker's impact on longer term health outcomes. As a single biomarker or next-generation diagnostic in oral health can inform decisions about numerous downstream diagnosis-treatment combinations, early stage "upstream" HTA is crucial in prioritizing the most valuable diagnostic applications to pursue first. For the vast array of oral health biomarkers currently developed, early HTA is necessary to timely and iteratively assess their comparative effectiveness and anticipate the inevitable questions about value for money from regulators and payers.
authors.affiliation: 1 Fred Hutchinson Cancer Research Center, Hutchinson Institute for Cancer Outcomes Research , Seattle, Washington, United States .|2 School of Pharmacy, University of Washington , Seattle, Washington, United States .|3 Panaxea bv , Enschede, The Netherlands .
authors.forename: Lotte M G
authors.initials: LM
authors.lastname: Steuten
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D006801:Humans; D057285:Precision Medicine / Q000379:methods*; D013597:Systems Analysis
chemical_list: D015415:Biomarkers